Treatment of elderly patients with chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Treatment of elderly patients with chronic lymphocytic leukemia.

Treatment of elderly patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37386705

about

Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia Idelalisib and rituximab in relapsed chronic lymphocytic leukemia Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach.A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 Practical approach to management of chronic lymphocytic leukemia Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study.Chronic lymphocytic leukemia in less fit patients: "slow-go".Treatment of older patients with chronic lymphocytic leukemia.The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy.Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia.Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands.Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma.Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.

P2860

Q26775986-C7855142-E75F-4A75-B371-79324E860E5A Q28087378-6E2B61F5-42CE-4EB1-88A8-B66374535765 Q28306347-0B10F7BD-9F50-43CF-BC7B-621516CB8606 Q33394308-875B2E07-3E96-4B3E-AA3F-17A9EDAB0FF7 Q33409149-FA546770-DBA1-4FDD-BC83-26C8EA8B8921 Q33425372-699676CD-0109-4B15-AC3E-EC8B5CB15FB9 Q33846793-FE83321E-2BF6-400C-902D-740AAC6BCA95 Q34008866-88333A2E-D4B3-4F24-A825-EEA397309FE0 Q34009041-278CAE60-2FA1-4E79-B5DB-D01E47B65C28 Q34255124-E5A146CC-8F30-4866-861D-D930E33B9011 Q34272532-84230D46-9A77-435E-9198-BE32B876E985 Q35110582-E171F5D3-2FB6-4775-BC33-908B0819E38D Q35794457-BF6F94B1-31BA-49E7-8CD6-447816999C43 Q36161529-61DF7B5A-8AAA-405B-8197-1C55A97F589A Q36251887-18C637DC-E622-4919-8777-FE51E3715587 Q36519986-1667604B-6E43-49FD-A196-4689D5B0F83F Q36826893-B6365BAB-F449-4D7D-88E8-ED0EE9D29B3E Q36845277-9FDF69FE-906D-43BF-956B-71FD12A81D61 Q37879960-1D2E7DD4-FD0A-41BE-99B0-0BE3831AE6DC Q37903038-A10DFC65-D290-4A45-806C-B082BF25153A Q37974861-DAEF07A1-C7EC-490B-9FF4-15455A0D020E Q38126946-77632234-1E24-4114-AC7E-C08CFA870227 Q38132818-6BFAC269-DB9A-479D-ABFB-D37A19DF75D1 Q38579008-ADEDB015-7A44-4FDE-A074-AC5D5583C53D Q38676408-C494BB61-C5EC-4FC2-ABD2-B87D6FAA4B47 Q38791698-F064E37B-81A6-4EED-82BC-45BC42FDEB20 Q38850667-F2EF0A43-FED1-4380-9B83-AB9C390EFD99 Q38982682-200F01F3-D084-44EF-8AB7-A951C1949A18 Q39475634-6BA50F25-54C6-48D5-B215-2DD5E936763B Q47094907-160DC7F8-6DA4-4541-96D4-B6FA0D59F8CB Q48070488-3C29E9E9-CE9F-4C05-B076-D32ECABFA0C6 Q52646820-71E0DE4B-E172-4EF6-A289-647763811CF2 Q53244764-F2AB25AD-1348-437C-9F7E-4614E426D0FE Q54407620-312B72C4-2F3C-433B-BC64-B06858126E88

P2860

Treatment of elderly patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37386705

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Treatment of elderly patients with chronic lymphocytic leukemia.

@en

Treatment of elderly patients with chronic lymphocytic leukemia.

@nl

type

label

Treatment of elderly patients with chronic lymphocytic leukemia.

@en

Treatment of elderly patients with chronic lymphocytic leukemia.

@nl

prefLabel

Treatment of elderly patients with chronic lymphocytic leukemia.

@en

Treatment of elderly patients with chronic lymphocytic leukemia.

@nl

P1433

Q37386705-F378B0E0-E24C-4E86-B840-58B28650951E

P1476

Q37386705-6B7D44EE-593F-445E-8C33-819E5A0C079E

P2093

Q37386705-40082009-0A40-486D-A554-81AB113D25D7

P2860

Q37386705-09ABFC4C-74AD-4323-814E-AC6132B21866

Q37386705-213EB93D-D403-4565-A8A3-12F66279BB39

Q37386705-2CF41485-A344-45F9-ADC7-BD916D8C92F6

Q37386705-43182909-2D64-47F5-B877-EFB699AAB4A1

Q37386705-4428B370-016B-496D-9C94-DEB892BED9B6

Q37386705-47AE7568-DD77-4A9A-832A-568AF9BC6660

Q37386705-493DF3A1-6B80-496E-B7E1-61FE324878CD

Q37386705-59EEA533-45D5-458B-AE53-A66A69E5364F

Q37386705-61D7E415-74B2-4AB3-BBBA-6ED8B08312BF

Q37386705-627F5AE8-E851-4A7D-B5B4-ABFC0483172C

P304

Q37386705-9E91E694-9FFD-4726-B5E8-68801CA1290B

P31

Q37386705-A157BA3C-3499-4914-9FC9-D906FD08B77F

P356

Q37386705-8F8670DC-2D7E-4A22-BB60-C1EAABF3EE19

P433

Q37386705-A5A42EF3-459C-409F-B9D2-63E1E7948B06

P478

Q37386705-62ACBA8A-2CA1-4D35-B1A9-1B9E7976195B

P50

Q37386705-5A85E4F5-347D-4D67-AE52-7E5183DE0C92

Q37386705-E7C50B16-1B02-45C4-A1E3-28CD56D4FB1D

Q37386705-FBAE77B4-E685-4D12-A062-2D7618F53AC8

P577

Q37386705-3D1BC413-35F1-403F-A3AB-57B6C8E617D5

P698

Q37386705-DDB5DB75-A2F7-4F4C-BFCC-28B7A68ED406

P921

Q37386705-631AE7C5-9F5E-42D1-B1FF-9FD69B4ADD5F

Q37386705-8D148765-6F68-4BAC-8209-A57BBF4E8CC6

Q37386705-BB336E63-668F-47D8-8704-D25A8E4C1385

P356

10428190802688517

P1433

Leukemia & Lymphoma

P1476

Treatment of elderly patients with chronic lymphocytic leukemia.

@en

P2093

Valentin Goede

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Genomic aberrations and survival in chronic lymphocytic leukemia

Prediction of creatinine clearance from serum creatinine

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

P304

171-178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190802688517

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

Barbara Eichhorst

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19197731

http://www.w3.org/2001/XMLSchema#string

P921